logo-loader
AIM ImmunoTech Inc.

Hemispherx Biopharma launches $8M rights issue to fund cancer drug trials

The company is making great strides in using its therapy Ampligen as an immuno-oncology agent to fight multiple types of cancer

cancer in headline
Under the offering, shareholders can purchase up to 8,000 units at $1,000 each

Hemispherx Biopharma Inc (NYSE American:HEB) has lodged a prospectus for an $8 million rights offering to purchase up to 8,000 units at $1,000 each as it looks to raise money to fund trials for its anti-cancer agent Ampligen.

Under the proposed rights offering, Hemispherx will distribute to its shareholders and to holders of certain options and warrants as of February 14, one non-transferable subscription right for each share of stock held on the record date.

READ: Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study

Each right permits the shareholder to purchase one unit at a subscription price of $1,000, consisting of one share of Series B Convertible Preferred stock (with a face value of $1,000) and 4,000 five-year warrants, each with an exercise price of $0.25.

“We are extremely pleased with the progress to date, moving Ampligen into immuno-oncology clinical trials for evaluation as an anti-cancer agent. Our use of a rights offering allows those stockholders who participate in the offering to help fund the Company and benefit from our future work,” said Thomas Equels, CEO of Hemispherx, in a statement.

The rights offering is expected to expire on or about March 1, 2019. Maxim Group and Ascendiant Capital Markets LLC have been hired as dealer-managers in the rights offering.

Hemispherx’s flagship products include the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx shares closed up by 11% to hit $0.26 on Wednesday.

Contact Ellen Kelleher at [email protected]

 

Quick facts: AIM ImmunoTech Inc.

Price: $1.84

Market: NYSE
Market Cap: $4.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019

2 min read